カテゴリ： GlobalData, アメリカ, 企業調査

Biohaven Pharmaceutical Holding Company Ltd (BHVN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C12391
◆発行会社（調査会社）：GlobalData
◆発行日：2018年12月
◆ページ数：94
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that includes two product candidates such as rimegepant (BHV-3000) for the acute treatment of migraine, and BHV-3500 for the prevention of a chronic and episodic migraine. Its glutamate modulation platform includes product candidates such as trigriluzole for the treatment of obsessive-compulsive disorder (OCD) and Alzheimer’s disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS); and BHV-5000 for treating symptoms associated with Rett syndrome and other neuropsychiatric indications. Biohaven is headquartered in New Haven, Connecticut, the US.

Biohaven Pharmaceutical Holding Company Ltd (BHVN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Kleo Pharma Raises USD21 Million in Series B Financing 14
Biohaven Pharma Raises USD80 Million in Venture Financing 15
Kleo Pharma Raises Funds through Series A Financing 17
Partnerships 18
Biohaven Pharma and University of Connecticut Enter into Research Agreement 18
Biohaven Pharma Enters into Partnership with Alzheimer’s Disease Cooperative Study 19
Licensing Agreements 20
Biohaven Pharma Enters into Licensing Agreement with University of Connecticut 20
Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 21
Catalent UK Swindon Zydis Enters into Licensing Agreement with Biohaven Pharma 22
Biohaven Pharma Enters into Licensing Agreement with AstraZeneca 23
Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 24
Biohaven Pharma Enters into Licensing Agreement with Rutgers, The State University of New Jersey 26
Biohaven Pharma Enters into Licensing Agreement with ALS Biopharma and Fox Chase Chemical Diversity Center 28
Biohaven Pharma Enters into Licensing Agreement with Catalent Pharma Solutions 29
Biohaven Pharma Enters into Licensing Agreement with General Hospital 30
Biohaven Pharma Enters into Licensing Agreement with Yale University 31
Equity Offering 32
Biohaven Pharma Plans to Raise up to USD4 Million in Public Offering of Shares 32
Biohaven Pharma Raises USD50 Million in Private Placement of Shares 33
Biohaven Pharma to Raise Funds through Public Offering of Shares 34
Biohaven Pharmaceutical Raises USD55 Million in Private Placement of Shares 35
Biohaven Pharma Raises USD193.5 Million in IPO 36
Biohaven Pharma Raises USD20 Million in Second Tranche of Private Placement of Shares 38
Biohaven Pharma Raises USD2.3 Million in Private Placement of Shares 40
Biohaven Pharma Raises USD4.1 Million in First Tranche of Private Placement of Shares 41
Asset Transactions 42
Royalty Pharma Acquires Approximately 2% Royalty Rights on Global Annual Net Sales of Rimegepant from Biohaven Pharma 42
Acquisition 43
Portage Biotech Acquires 54% Stake In Biohaven Pharma For USD3.5 Million 43
Biohaven Pharmaceutical Holding Company Ltd – Key Competitors 44
Biohaven Pharmaceutical Holding Company Ltd – Key Employees 45
Biohaven Pharmaceutical Holding Company Ltd – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
Aug 14, 2018: Biohaven Pharmaceuticals announces second quarter 2018 financial results 47
May 15, 2018: Biohaven Pharmaceuticals Announces First Quarter 2018 Financial Results 50
Mar 06, 2018: Biohaven Pharmaceuticals Announces Fourth Quarter And Full Year 2017 Financial Results 52
Nov 14, 2017: Biohaven Pharmaceuticals Reports Third Quarter 2017 Financial And Business Results 54
Aug 14, 2017: Biohaven Pharmaceuticals Reports Second Quarter 2017 Financial And Business Results 56
Jun 19, 2017: Biohaven Pharmaceuticals Reports First Quarter 2017 Financial and Business Results 58
Corporate Communications 60
Sep 12, 2018: Biohaven Pharmaceutical appoints Bob Repella as board director 60
Nov 13, 2017: Biohaven Expands Finance Team With Appointment Of Senior Vice President 61
Oct 25, 2017: Biohaven Adds Clifford Bechtold as Chief Operating Officer 62
Aug 04, 2017: Biohaven Appoints Julia P. Gregory to Board of Directors 63
Jun 22, 2017: Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives 64
Mar 07, 2017: Biohaven Appoints Two New Directors To Board 65
Product News 66
12/21/2017: Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder 66
11/01/2017: Biohaven Announces FDA Clearance of IND Application for Sublingual BHV-0223 in Patients with Amyotrophic Lateral Sclerosis 67
10/02/2017: Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia Phase 2/3 Trial 68
Sep 11, 2017: Biohaven To Provide Development Program Update At The Morgan Stanley 15th Annual Global Healthcare Conference 70
08/07/2017: Biohaven Completes Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia: Expected Topline Data Advanced To Fourth Quarter Of 2017 71
08/03/2018: Biohaven enrols first patient in Phase ll/lll trial of trigriluzole 72
03/01/2018: Biohaven Announces Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis Orally Dissolving Tablet 73
01/09/2018: Biohaven announces Positive results from Bioequivalence study with sublingual BHV-0223 Zydis Orally Dissolving Tablet 74
Product Approvals 75
Jul 24, 2018: Biohaven initiates Phase 2/3 clinical trial of trigriluzole 75
May 09, 2018: Biohaven Initiates Expanded Access Program for Sublingual BHV-0223 ZYDIS Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS) 76
Oct 24, 2017: Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder 78
Jul 06, 2017: Biohavens BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome 79
May 15, 2017: Biohaven’s Trigriluzole Receives Fast Track Designation From U.S. FDA 80
Clinical Trials 81
Apr 22, 2018: Biohaven Announces Robust Clinical Data with Single Dose Rimegepant That Defines Acute and Durable Benefits to Patients: The First Oral CGRP Receptor Antagonist to Deliver Positive Data on Pain Freedom and Most Bothersome Symptom in Two Pivotal Phase 3 Trials in Acute Treatment of Migraine 81
Apr 19, 2018: Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data to be Released at Investor Event Held Concurrently with the 2018 American Academy of Neurology Meeting in Los Angeles 82
Mar 26, 2018: Biohaven Announces Successful Achievement of Both Co-Primary Regulatory Endpoints in Two Pivotal Phase 3 Trials of Rimegepant an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine 83
Mar 06, 2018: Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODT In The Acute Treatment Of Migraine 84
Jan 18, 2018: Biohaven Announces Initiation Of Clinical Development For BHV-5000, A Novel Low-Trapping NMDA Antagonist 85
Nov 27, 2017: Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant 86
Nov 20, 2017: Biohaven Receives Agreement From FDA on Initial Pediatric Study Plan for Rimegepant, a Second Generation Oral CGRP-Receptor Antagonist for the Acute Treatment of Migraine 87
Nov 16, 2017: Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine 88
Nov 06, 2017: Biohaven Doses First Subject in Pivotal Bioequivalence Study with Sublingual BHV-0223 89
Oct 30, 2017: Biohaven Announces First Patient Treated In Clinical Research Collaboration At Rutgers Cancer Institute 90
Jul 31, 2017: Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine 91
Jul 24, 2017: Biohaven Enrolls First Patient in Pivotal Phase 3 Clinical Trial of Oral Rimegepant for the Acute Treatment of Migraine 92
May 30, 2017: Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole 93
Appendix 94
Methodology 94
About GlobalData 94
Contact Us 94
Disclaimer 94

List of Tables
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Biohaven Pharmaceutical Holding Company Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kleo Pharma Raises USD21 Million in Series B Financing 14
Biohaven Pharma Raises USD80 Million in Venture Financing 15
Kleo Pharma Raises Funds through Series A Financing 17
Biohaven Pharma and University of Connecticut Enter into Research Agreement 18
Biohaven Pharma Enters into Partnership with Alzheimer's Disease Cooperative Study 19
Biohaven Pharma Enters into Licensing Agreement with University of Connecticut 20
Biohaven Therapeutics Enters into Licensing Agreement with AstraZeneca 21
Catalent UK Swindon Zydis Enters into Licensing Agreement with Biohaven Pharma 22
Biohaven Pharma Enters into Licensing Agreement with AstraZeneca 23
Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 24
Biohaven Pharma Enters into Licensing Agreement with Rutgers, The State University of New Jersey 26
Biohaven Pharma Enters into Licensing Agreement with ALS Biopharma and Fox Chase Chemical Diversity Center 28
Biohaven Pharma Enters into Licensing Agreement with Catalent Pharma Solutions 29
Biohaven Pharma Enters into Licensing Agreement with General Hospital 30
Biohaven Pharma Enters into Licensing Agreement with Yale University 31
Biohaven Pharma Plans to Raise up to USD4 Million in Public Offering of Shares 32
Biohaven Pharma Raises USD50 Million in Private Placement of Shares 33
Biohaven Pharma to Raise Funds through Public Offering of Shares 34
Biohaven Pharmaceutical Raises USD55 Million in Private Placement of Shares 35
Biohaven Pharma Raises USD193.5 Million in IPO 36
Biohaven Pharma Raises USD20 Million in Second Tranche of Private Placement of Shares 38
Biohaven Pharma Raises USD2.3 Million in Private Placement of Shares 40
Biohaven Pharma Raises USD4.1 Million in First Tranche of Private Placement of Shares 41
Royalty Pharma Acquires Approximately 2% Royalty Rights on Global Annual Net Sales of Rimegepant from Biohaven Pharma 42
Portage Biotech Acquires 54% Stake In Biohaven Pharma For USD3.5 Million 43
Biohaven Pharmaceutical Holding Company Ltd, Key Competitors 44
Biohaven Pharmaceutical Holding Company Ltd, Key Employees 45
Biohaven Pharmaceutical Holding Company Ltd, Subsidiaries 46

List of Figures
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Biohaven Pharmaceutical Holding Company Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

★海外企業調査レポート[Biohaven Pharmaceutical Holding Company Ltd (BHVN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Robinson Helicopter Company, Inc.：企業の戦略・SWOT・財務分析
    Robinson Helicopter Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Robinson Helicopter Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Active Biotech AB (ACTI)：製薬・医療：M&Aディール及び事業提携情報
    Summary Active Biotech AB (Active Biotech) is a biotechnology company that develops and commercializes pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company’s key products in development include Laquinimod (neurodegenerative diseases); Anyara (cancer); Tasqu …
  • Nippon Express Co Ltd (9062)：企業の財務・戦略的SWOT分析
    Nippon Express Co Ltd (9062) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Culp Inc (CULP)：企業の財務・戦略的SWOT分析
    Culp Inc (CULP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • M1 Ltd (B2F)：企業の財務・戦略的SWOT分析
    M1 Ltd (B2F) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Avedro Inc：医療機器：M&Aディール及び事業提携情報
    Summary Avedro Inc (Averdro) is a medical device company that manufactures and distributes cross-linking systems and riboflavin ophthalmic products. The company’s products include mosaic systems for PiXL, lasik xtra, and accelerated cross-linking; KXL systems for lasik xtra and accelerated cross-lin …
  • Shimadzu Corp (7701)
    Shimadzu Corp (7701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Puretech Health plc (PRTC)：企業の財務・戦略的SWOT分析
    Summary Puretech Health plc (Puretech), formerly PureTech Ventures LLC, is a biopharmaceutical company that develops medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company develops a microbiome immune system drug-discovery platform and drug ca …
  • Iron Mountain Inc (IRM)：企業の財務・戦略的SWOT分析
    Iron Mountain Inc (IRM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Goodfellow Inc (GDL)：企業の財務・戦略的SWOT分析
    Goodfellow Inc (GDL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Koninklijke Ten Cate NV：企業の戦略的SWOT分析
    Koninklijke Ten Cate NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • RPG Cables Limited：企業の戦略・SWOT・財務情報
    RPG Cables Limited - Strategy, SWOT and Corporate Finance Report Summary RPG Cables Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Cal-Maine Foods Inc (CALM)：企業の財務・戦略的SWOT分析
    Cal-Maine Foods Inc (CALM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Formula Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Formula Pharmaceuticals Inc (Formula Pharmaceuticals) is a biopharmaceutical company that develops chimeric antigen receptor immunotherapy for oncology and autoimmune diseases. The company provides its pipeline products such as CIK-CAR.CD19, used as B-lymphocyte surface antigen; CIK-CAR.CD33 …
  • Bisnode AB：企業のM&A・事業提携・投資動向
    Bisnode AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bisnode AB Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Accugenomics Inc-医療機器分野：企業M&A・提携分析
    Summary Accugenomics Inc (Accugenomics) is a provider of molecular diagnostics for cancer. The company develops and markets gene expression tests to diagnose and monitor cancer treatment. It offers gene expression tests including lung cancer risk test, standardized BCR-ABL molecular diagnostics test …
  • China Petroleum & Chemical Corp (600028)：電力：M&Aディール及び事業提携情報
    Summary China Petroleum & Chemical Corp (Sinopec Corp), a subsidiary of China Petrochemical Corporation, is a vertically integrated energy and chemical company. It is involved in the oil and gas exploration and production, extraction, pipeline transmission and marketing; oil refining; and production …
  • Mincor Resources NL：企業の戦略・SWOT・財務情報
    Mincor Resources NL - Strategy, SWOT and Corporate Finance Report Summary Mincor Resources NL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Oaktree Capital Group Llc：企業の戦略・SWOT・財務分析
    Oaktree Capital Group Llc - Strategy, SWOT and Corporate Finance Report Summary Oaktree Capital Group Llc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • AB Science SA (AB)：製薬・医療：M&Aディール及び事業提携情報
    Summary AB Science SA (ABS) is a pharmaceutical company focused on discovery, development, and commercialization of protein kinase inhibitors. The company's lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆